PURPOSE: To report the results of photodynamic therapy in myopic patients with juxtafoveal choroidal neovascularization (CNV). DESIGN: Interventional case series. METHODS: Three consecutive myopic patients with juxtafoveal CNV were treated by photodynamic therapy with the same protocol as the one used to treat subfoveal CNV. Visual acuity was measured on Early Treatment Diabetic Retinopathy Study (ETDRS) charts by an independent observer. Fluorescein angiography was performed 6 and 12 weeks after photodynamic therapy and then every 12 weeks. RESULTS: In all three patients, one treatment of photodynamic therapy using verteporfin resulted in the involution of the CNV and improvement in best-corrected visual acuity from 20/50 or 20/40 to 20/25 or more. No retreatment was required during follow-up, which lasted for 12 to 24 months (mean = 17 months). CONCLUSION: Photodynamic therapy may be an effective treatment for juxtafoveal CNV in myopic eyes.
PURPOSE: To report the results of photodynamic therapy in myopic patients with juxtafoveal choroidal neovascularization (CNV). DESIGN: Interventional case series. METHODS: Three consecutive myopic patients with juxtafoveal CNV were treated by photodynamic therapy with the same protocol as the one used to treat subfoveal CNV. Visual acuity was measured on Early Treatment Diabetic Retinopathy Study (ETDRS) charts by an independent observer. Fluorescein angiography was performed 6 and 12 weeks after photodynamic therapy and then every 12 weeks. RESULTS: In all three patients, one treatment of photodynamic therapy using verteporfin resulted in the involution of the CNV and improvement in best-corrected visual acuity from 20/50 or 20/40 to 20/25 or more. No retreatment was required during follow-up, which lasted for 12 to 24 months (mean = 17 months). CONCLUSION: Photodynamic therapy may be an effective treatment for juxtafoveal CNV in myopic eyes.
Authors: Joachim Wachtlin; Andrea Stroux; Andreas Wehner; Heinrich Heimann; Michael H Foerster Journal: Graefes Arch Clin Exp Ophthalmol Date: 2004-12-11 Impact factor: 3.117
Authors: Ute E K Schnurrbusch; Claudia Jochmann; Peter Wiedemann; Sebastian Wolf Journal: Graefes Arch Clin Exp Ophthalmol Date: 2005-03-15 Impact factor: 3.117
Authors: Wai-Man Chan; Timothy Y Y Lai; Yasuo Tano; David T L Liu; Kenneth K W Li; Dennis S C Lam Journal: Jpn J Ophthalmol Date: 2006 Mar-Apr Impact factor: 2.211